Walleye Capital
LRMR icon

Walleye Capital’s Larimar Therapeutics LRMR Stock Holding History

Walleye Capital’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-54,400
Closed -$176K – 4886
2025
Q3 		$176K Buy
+54,400
New +$204K ﹤0.01% 3404
2025
Q2 		– Sell
-17,166
Closed -$36.9K – 4827
2025
Q1 		$36.9K Buy
+17,166
New +$54.3K ﹤0.01% 3917
2024
Q3 		– Sell
-10,939
Closed -$79.3K – 5620
2024
Q2 		$79.3K Sell
10,939
-30,110
-73% -$231K ﹤0.01% 4804
2024
Q1 		$312K Sell
41,049
-17,501
-30% -$136K ﹤0.01% 3631
2023
Q4 		$266K Sell
58,550
-148,333
-72% -$500K ﹤0.01% 3466
2023
Q3 		$817K Buy
206,883
+15,154
+8% +$57.3K ﹤0.01% 2427
2023
Q2 		$600K Buy
+191,729
New +$782K ﹤0.01% 2293

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Walleye Capital's LRMR Position: Q4 2025 in Review

Walleye Capital sold out of Larimar Therapeutics (LRMR) in Q4 2025, closing a stake of 54,400 shares — an estimated $176K sold.

Walleye Capital first reported a position in LRMR in Q2 2023 and held it in 7 quarters. The position peaked at $817K in Q3 2023. 136 funds tracked by Wall St. Rank hold LRMR as of Q4 2025.

  • Walleye Capital reported no remaining Larimar Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Walleye Capital sold 54,400 Larimar Therapeutics shares in Q4 2025, an estimated $176K.
  • Walleye Capital first reported a position in Larimar Therapeutics in Q2 2023 and held it in 7 quarters.
  • Walleye Capital's Larimar Therapeutics position peaked at $817K in Q3 2023.
  • 136 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q4 2025.

Based on Walleye Capital's 13F filing for Q4 2025, filed 13 Feb 2026.